The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers.
Denis MalvyAnne-Marie TaburetXavier de LamballerieFrance MentréFabrice ExtramianaPublished in: PLoS neglected tropical diseases (2020)
Keyphrases